152 related articles for article (PubMed ID: 9433338)
21. Risperidone in treatment-refractory schizophrenia.
Wirshing DA; Marshall BD; Green MF; Mintz J; Marder SR; Wirshing WC
Am J Psychiatry; 1999 Sep; 156(9):1374-9. PubMed ID: 10484947
[TBL] [Abstract][Full Text] [Related]
22. Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays.
Smith RC; Baumgartner R; Misra CH; Mauldin M; Shvartsburd A; Ho BT; DeJohn C
Arch Gen Psychiatry; 1984 Nov; 41(11):1044-9. PubMed ID: 6497566
[TBL] [Abstract][Full Text] [Related]
23. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
[TBL] [Abstract][Full Text] [Related]
24. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
[TBL] [Abstract][Full Text] [Related]
25. Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients.
Yasui-Furukori N; Kondo T; Mihara K; Suzuki A; Inoue Y; Kaneko S
J Clin Psychopharmacol; 2003 Oct; 23(5):435-40. PubMed ID: 14520118
[TBL] [Abstract][Full Text] [Related]
26. Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder.
Volavka J; Cooper TB; Czobor P; Meisner M
Psychopharmacol Bull; 1996; 32(1):75-9. PubMed ID: 8927679
[TBL] [Abstract][Full Text] [Related]
27. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
[TBL] [Abstract][Full Text] [Related]
28. Blood levels of haloperidol and clinical outcome in schizophrenia.
Doddi S; Rifkin A; Karajgi B; Cooper T; Borenstein M
J Clin Psychopharmacol; 1994 Jun; 14(3):187-95. PubMed ID: 8027415
[TBL] [Abstract][Full Text] [Related]
29. Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia.
Kelly MW; Perry PJ; Coryell WH; Miller DD; Arndt SV
Psychopharmacology (Berl); 1990; 102(4):514-20. PubMed ID: 2096408
[TBL] [Abstract][Full Text] [Related]
30. Serum prolactin as a correlate of clinical response to haloperidol.
Van Putten T; Marder SR; Mintz J
J Clin Psychopharmacol; 1991 Dec; 11(6):357-61. PubMed ID: 1770154
[TBL] [Abstract][Full Text] [Related]
31. Factors affecting the clinical response to haloperidol therapy in schizophrenia.
Bareggi SR; Mauri M; Cavallaro R; Regazzetti MG; Moro AR
Clin Neuropharmacol; 1990; 13 Suppl 1():S29-34. PubMed ID: 2379182
[TBL] [Abstract][Full Text] [Related]
32. Comparative efficacy of red cell and plasma haloperidol as predictors of clinical response in schizophrenia.
Smith RC; Baumgartner R; Shvartsburd A; Ravichandran GK; Vroulis G; Mauldin M
Psychopharmacology (Berl); 1985; 85(4):449-55. PubMed ID: 2862652
[TBL] [Abstract][Full Text] [Related]
33. The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics.
Khot V; DeVane CL; Korpi ER; Venable D; Bigelow LB; Wyatt RJ; Kirch DG
J Clin Psychopharmacol; 1993 Apr; 13(2):120-7. PubMed ID: 8463444
[TBL] [Abstract][Full Text] [Related]
34. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients.
Ko GN; Korpi ER; Kirch DG
J Clin Psychopharmacol; 1989 Jun; 9(3):186-90. PubMed ID: 2661607
[TBL] [Abstract][Full Text] [Related]
35. The relationship between plasma haloperidol concentrations and clinical results.
Palao DJ; Araúxo A; Haro JM; Brunet M; Bernardo M
Arch Gen Psychiatry; 1996 Dec; 53(12):1167-9. PubMed ID: 8956684
[No Abstract] [Full Text] [Related]
36. Clinical implications of determination of plasma haloperidol levels.
Santos JL; Cabranes JA; Almoguera I; Ramos JA; Vazquez C; Angeles F
Acta Psychiatr Scand; 1989 Apr; 79(4):348-54. PubMed ID: 2735205
[TBL] [Abstract][Full Text] [Related]
37. Determination of plasma haloperidol concentrations by radioreceptor assay in schizophrenia: clinical utility.
Santos JL; Ramos JA; Prieto P; Almoguera I; Vazquez C; Rubio ME; Cabranes JA
Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(6):917-25. PubMed ID: 2813809
[TBL] [Abstract][Full Text] [Related]
38. Risperidone in the treatment of schizophrenia.
Marder SR; Meibach RC
Am J Psychiatry; 1994 Jun; 151(6):825-35. PubMed ID: 7514366
[TBL] [Abstract][Full Text] [Related]
39. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients.
Van Putten T; Marder SR; Mintz J
Arch Gen Psychiatry; 1990 Aug; 47(8):754-8. PubMed ID: 2378546
[TBL] [Abstract][Full Text] [Related]
40. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
